fludarabine has been researched along with Opportunistic Infections in 44 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 11 (25.00) | 18.2507 |
2000's | 26 (59.09) | 29.6817 |
2010's | 7 (15.91) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, BA; Ding, JH; Ge, Z; Sun, AN; Wu, DP; Yu, ZP | 1 |
Ghavamzadeh, A; Hamdi, A; Hamidieh, AA; Nabavi, M; Pourpak, Z | 1 |
Blazar, BR; DeFor, TE; Dusenbery, KE; MacMillan, ML; Slungaard, A; Wagner, JE; Weisdorf, DJ; Young, JA; Zierhut, H | 1 |
Bolam, S; Follows, G; Gambell, J; Hillmen, P; Jack, A; Johnson, PW; Johnson, S; Kirkwood, AA; Kruger, A; Linch, D; Pocock, C; Rule, S; Seymour, JF; Smith, P; Toncheva, M; Walewski, J | 1 |
Bhandari, S; Cranfield, T; Simon, G; Walker, M | 1 |
Bauduer, F | 1 |
Aksoy, S; Dizdar, O; Harputluoğlu, H; Hayran, M | 1 |
Bahlis, NJ; Barr, PM; Cooper, BW; Dowlati, A; Fu, P; Gerson, SL; Horvath, N; Koc, ON; Lazarus, HM; Snell, MR | 1 |
Brewer, SC; Cleveland, KO; Gelfand, MS | 1 |
Abraham, J; Andritsos, L; Benson, DM; Blum, W; Bunner, P; Craig, M; Cumpston, A; Devine, SM; Efebera, Y; Elder, P; Garzon, R; Gibson, L; Hamadani, M; Hofmeister, C; Leadmon, S; Penza, S; Phillips, GS; Remick, SC; Tse, W | 1 |
Ajana, F; Ettahar, N; Legout, L; Massongo, M; Patoz, P; Rose, C; Senneville, E | 1 |
Brettman, L; Cooper, MR; Freter, CE; Mercier, RJ; Mitchell, BS; Rai, KR; Santábarbara, P; Stadtmauer, EA; Wacker, B | 1 |
Annunziata, M; Copia, C; D'Amico, MR; De Simone, M; Ferrara, F; Palmieri, S; Pocali, B; Schiavone, EM; Vecchio, LD | 1 |
Amadori, S; Ballatore, G; Caravita, T; Catalano, G; Cristina Cox, M; Cudillo, L; Cupelli, L; Dentamaro, T; Fabritiis Pd, Pd; Picardi, A; Venditti, A | 1 |
Al-Kadhimi, Z; Angelopoulou, M; Cohen, S; Falk, PM; Forman, SJ; Fung, HC; Kogut, N; Krishnan, AY; Nademanee, A; O'Donnell, MR; Parker, P; Popplewell, L; Rodriguez, R; Sahebi, F; Schriber, J; Senitzer, D; Slovak, M; Smith, D; Snyder, DS; Somlo, G; Spielberger, R; Stein, A | 1 |
Gadea, I; Llamas, P; Prieto, E; Román, A; Santos, AB; Subirá, D; Tomás, JF | 1 |
Bowen, A; Catovsky, D; Hendry, L; Matutes, E; Swansbury, J | 1 |
Grigg, AP; Januszewicz, EH; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, MM | 1 |
Hartwig, UF; Herr, W; Huber, C; Kolbe, K; Kreiter, S; Meyer, RG; Schneider, PM; Ullmann, AJ; Wehler, T; Winkelmann, N | 1 |
Chun, K; Daly, A; Gupta, V; Hasegawa, W; Kamel-Reid, S; Kiss, T; Lipton, JH; Messner, H; Minden, M; Tsang, R; Yi, QL | 1 |
Benetatos, L; Bourantas, KL; Hatzimichael, E; Vassou, A | 1 |
Abdul-Hai, A; Ackerstein, A; Aker, M; Bitan, M; Gesundheit, B; Lvovich, A; Miron, S; Or, R; Resnick, IB; Samuel, S; Shapira, MY; Slavin, S; Tsirigotis, PD; Yoffe, L; Zilberman, I | 1 |
Abidi, MH; Alangaden, G; Chandrasekar, PH; Heilbrun, LK; Klein, JL; Mellon-Reppen, S; Narreddy, S; Peres, E; Smith, D | 1 |
Bunker, CB; Chapman, A; Dearden, CE; Dungarwalla, M; Field-Smith, A; Jameson, C; Matutes, E; Riley, U | 1 |
Bacchu, S; Fegan, C; Neal, J | 1 |
Huisman, CA; Laros-van Gorkom, BA; Schipperus, MR; Wijermans, PW | 1 |
Huisman, C; Lokhorst, HM; Meijer, E; Petersen, EJ; Verdonck, LF | 1 |
Byrd, JC; Diehl, LF; Hargis, JB; Hospenthal, DR; Kester, KE; Knutson, SW | 1 |
Girmenia, C; Mauro, FR; Rahimi, S | 1 |
de Marie, S; Leenders, A; Sonneveld, P | 1 |
Björkholm, M; Celsing, F; Runarsson, G; Waldenström, J | 1 |
Juliusson, G; Liliemark, J | 1 |
Arning, M; Schneider, W; Südhoff, T | 1 |
Aitini, E; Costa, P; Forghieri, ME; Lazzarini, L; Luzzati, R; Nicolato, A; Perboni, G; Scalzini, A; Zinzani, PL | 1 |
Anaissie, EJ; Kantarjian, H; Keating, MJ; Kontoyiannis, DP; Lerner, S; O'Brien, S; Robertson, L | 1 |
Byrd, JC; Diehl, LF; Dow, NA; Hospenthal, DR; Howard, RS; McGrail, LH | 1 |
Arcaini, L; Astori, C; Baldanti, F; Bernasconi, C; Furione, M; Gerna, G; Lazzarino, M; Orlandi, E; Pagnucco, G; Paulli, M; Viglio, A | 1 |
Bowyer, JD; Gregson, RM; Horn, EH; Johnson, EM | 1 |
Harousseau, JL; Mahé, B; Milpied, N; Morin, O; Rapp, MJ; Vigouroux, S | 1 |
Hendrick, A | 1 |
Fezoui, H; Genet, P; Lionnet, F; Louvel, D; Pulik, M; Touahri, T | 1 |
Byrd, JC; Flynn, JM; Howard, RS; Perkins, JG | 1 |
Batlle, M; Feliu, E; Mate, JL; Millá, F; Ribera, JM; Rodríguez, L; Xicoy, B | 1 |
Lawrence, HJ; Perez, EA; Sanders, C | 1 |
3 review(s) available for fludarabine and Opportunistic Infections
Article | Year |
---|---|
Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Humans; Lymphoma; Neutropenia; Opportunistic Infections; Randomized Controlled Trials as Topic; Rituximab; Vidarabine | 2009 |
[Cryptococcal osteomyelitis in a patient with a lymphocytic leukemia treated with fludarabine-cyclophosphamide-rituximab].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cryptococcosis; Cryptococcus neoformans; Cutaneous Fistula; Cyclophosphamide; Diabetes Mellitus, Type 2; Female; Fungemia; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases, Fungal; Neutropenia; Opportunistic Infections; Osteolysis; Osteomyelitis; Rituximab; Vidarabine | 2013 |
Prophylactic strategies to meet infectious complications in fludarabine-treated CLL.
Topics: Antibiotic Prophylaxis; Antineoplastic Agents; Bacterial Infections; Granulocyte Colony-Stimulating Factor; Humans; Immunoglobulins, Intravenous; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Neutropenia; Opportunistic Infections; Salvage Therapy; Vidarabine | 1997 |
11 trial(s) available for fludarabine and Opportunistic Infections
Article | Year |
---|---|
A Randomized Study Comparing Stem Cell Transplantation Versus Conventional Therapy for Low- and Intermediate-Risk Myelodysplastic Syndromes Patients.
Topics: Adult; Busulfan; Cyclophosphamide; Disease Progression; Factor Analysis, Statistical; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Opportunistic Infections; Prognosis; Quality of Life; Risk Factors; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine; Young Adult | 2017 |
Alternative donor hematopoietic cell transplantation for Fanconi anemia.
Topics: Adolescent; Adult; Antilymphocyte Serum; Child; Child, Preschool; Cyclophosphamide; Enzyme Inhibitors; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Middle Aged; Opportunistic Infections; Survival Analysis; Tissue Donors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2015 |
The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Opportunistic Infections; Rituximab; Survival Analysis; Vidarabine | 2016 |
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Nervous System Diseases; Neutropenia; Opportunistic Infections; Pyrazines; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2009 |
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic, T-Cell; Male; Neutropenia; Opportunistic Infections; Pilot Projects; Remission Induction; Salvage Therapy; Survival Rate; Thrombocytopenia; Treatment Failure; Treatment Outcome; Vidarabine | 2002 |
Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Opportunistic Infections; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine | 2003 |
Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation.
Topics: Adult; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Opportunistic Infections; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Mycophenolic Acid; Opportunistic Infections; Premedication; Prospective Studies; Survival Analysis; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neutropenia; Opportunistic Infections; Remission Induction; Salvage Therapy; Survival Analysis; Vidarabine | 2004 |
Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older.
Topics: Acute Disease; Aged; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Opportunistic Infections; Siblings; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2005 |
Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
Topics: Adult; Age Factors; Aged; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Opportunistic Infections; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2008 |
30 other study(ies) available for fludarabine and Opportunistic Infections
Article | Year |
---|---|
Successful fludarabine-based hematopoietic stem cell transplantation in a pediatric patient with idiopathic CD4+ lymphocytopenia.
Topics: CD4-Positive T-Lymphocytes; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphopenia; Myeloablative Agonists; Opportunistic Infections; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2013 |
Images in haematology. Cerebral nocardiosis in a patient with lymphoplasmacytic lymphoma treated with fludarabine.
Topics: Aged, 80 and over; Antineoplastic Agents; Central Nervous System Bacterial Infections; Humans; Male; Nocardia Infections; Opportunistic Infections; Tomography, X-Ray Computed; Vidarabine; Waldenstrom Macroglobulinemia | 2008 |
[First-line therapy of chronic lymphocytic leukemia in the elderly: be careful with overtreatment].
Topics: Age Factors; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Cyclophosphamide; Drug Costs; Frail Elderly; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloablative Agonists; Opportunistic Infections; Risk Factors; Rituximab; Vidarabine | 2009 |
Rhodococcus equi pneumonia in a patient with fludarabine-treated chronic lymphocytic leukemia and CD4-lymphopenia.
Topics: Actinomycetales Infections; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents; Bronchoalveolar Lavage Fluid; CD4 Lymphocyte Count; Chronic Disease; Female; Humans; Leukemia, Lymphoid; Lymphopenia; Opportunistic Infections; Pneumonia, Bacterial; Rhodococcus equi; Vidarabine | 2010 |
Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.
Topics: Adult; Aged; Busulfan; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Opportunistic Infections; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2011 |
Aspergillus fumigatus: a rare cause of vertebral osteomyelitis.
Topics: Aspergillus fumigatus; Humans; Leukemia, B-Cell; Opportunistic Infections; Osteomyelitis; Purine Nucleosides; Spinal Diseases; Vidarabine | 2004 |
A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia; Lymphoma; Male; Middle Aged; Neoplasm Staging; Opportunistic Infections; Risk Factors; Vidarabine | 2004 |
Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.
Topics: Adult; Antigens, CD34; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Cell Fractionation; Cohort Studies; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Opportunistic Infections; Pneumonia, Bacterial; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2005 |
Cryptococcus lung infection complicating fludarabine treatment in a chronic lymphocytic leukemia patient.
Topics: Aged; Antifungal Agents; Antineoplastic Agents; Cryptococcosis; Fluconazole; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases, Fungal; Male; Opportunistic Infections; Radiography, Thoracic; Tomography, X-Ray Computed; Treatment Outcome; Vidarabine | 2007 |
Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen.
Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Child; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Mucositis; Opportunistic Infections; Pilot Projects; Quality of Life; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2006 |
Non-bacterial infections in allogeneic non-myeloablative stem cell transplant recipients.
Topics: Academies and Institutes; Antineoplastic Agents; Aspergillosis; Cyclophosphamide; Cytomegalovirus Infections; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Michigan; Middle Aged; Myeloablative Agonists; Neoplasms; Opportunistic Infections; Retrospective Studies; Review Literature as Topic; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2007 |
Cutaneous Mycobacterium chelonae infection in chronic lymphocytic leukaemia.
Topics: Agammaglobulinemia; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Humans; Immunocompromised Host; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Opportunistic Infections; Skin Diseases, Bacterial; Vidarabine | 2007 |
Cerebral toxoplasmosis in a patient with chronic lymphocytic leukaemia treated with fludarabine.
Topics: Aged, 80 and over; Antineoplastic Agents; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Opportunistic Infections; Toxoplasmosis, Cerebral; Vidarabine | 2007 |
Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Aspergillosis; CD52 Antigen; Drug Evaluation; Drug Resistance, Neoplasm; Glycoproteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Records; Netherlands; Opportunistic Infections; Pneumonia, Pneumocystis; Remission Induction; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome; Vidarabine | 2007 |
Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis.
Topics: Antineoplastic Agents; Biopsy; Bronchoscopy; Humans; Lung; Lung Diseases; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Opportunistic Infections; Pneumonia, Pneumocystis; Vidarabine | 1995 |
Late listeriosis after fludarabine plus prednisone treatment.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Listeriosis; Male; Opportunistic Infections; Prednisone; Time Factors; Vidarabine | 1994 |
Cryptococcal meningitis following fludarabine treatment for chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Meningitis, Cryptococcal; Middle Aged; Opportunistic Infections; Vidarabine | 1995 |
Successful intravenous immunoglobulin therapy for severe and persistent astrovirus gastroenteritis after fludarabine treatment in a patient with Waldenström's macroglobulinemia.
Topics: Aged; Gastroenteritis; Humans; Immunization, Passive; Immunocompromised Host; Immunoglobulins, Intravenous; Male; Mamastrovirus; Opportunistic Infections; Peptic Ulcer; Vidarabine; Virus Diseases; Waldenstrom Macroglobulinemia | 1995 |
Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Count; Cladribine; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Opportunistic Infections; Remission Induction; Retreatment; Survival Rate; Treatment Outcome; Vidarabine | 1996 |
Cryptococcal meningitis and intracranial tuberculoma in a patient with Waldenstrom's macroglobulinemia treated with fludarabine.
Topics: Antineoplastic Agents; Brain Diseases; Female; Humans; Immunosuppressive Agents; Meningitis, Cryptococcal; Middle Aged; Opportunistic Infections; Tuberculoma; Vidarabine; Waldenstrom Macroglobulinemia | 1998 |
Infections in patients with chronic lymphocytic leukemia treated with fludarabine.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Logistic Models; Neoplasm Staging; Opportunistic Infections; Prednisone; Retrospective Studies; Risk Factors; Vidarabine | 1998 |
Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study.
Topics: Aged; Female; Herpesviridae Infections; Humans; Immunosuppressive Agents; Lymphoproliferative Disorders; Male; Middle Aged; Opportunistic Infections; Prospective Studies; Vidarabine | 1999 |
The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Viral; Cyclophosphamide; Dexamethasone; Epstein-Barr Virus Infections; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Opportunistic Infections; Vidarabine; Virus Activation | 1999 |
Oochroconis gallopava endophthalmitis in fludarabine treated chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Endophthalmitis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mitosporic Fungi; Opportunistic Infections; Vidarabine | 2000 |
[Cryptococcus neoformans infection in hematologic malignancies].
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Cryptococcosis; Cryptococcus neoformans; Female; France; Hematologic Neoplasms; Humans; Immunity, Cellular; Lymphoproliferative Disorders; Male; Middle Aged; Opportunistic Infections; Retrospective Studies; Vidarabine | 2000 |
Fatal legionella pneumonia after fludarabine treatment in chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Fatal Outcome; Humans; Immunocompromised Host; Legionnaires' Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Opportunistic Infections; Vidarabine | 2001 |
Toxoplasmic encephalitis in a non-HIV patient with follicular lymphoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Immunocompromised Host; Interferon-alpha; Lymphoma, Follicular; Opportunistic Infections; Prednisone; Salvage Therapy; Teniposide; Toxoplasmosis, Cerebral; Vidarabine | 2002 |
Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Opportunistic Infections; Retrospective Studies; Risk Factors; Survival Rate; Vidarabine | 2002 |
Progressive multifocal leukoencephalopathy shortly after the diagnosis of follicular lymphoma in a patient treated with fludarabine.
Topics: Antineoplastic Agents; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Follicular; Male; Middle Aged; Opportunistic Infections; Time Factors; Vidarabine | 2002 |
Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine.
Topics: Antineoplastic Agents; Humans; Immunity, Cellular; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Opportunistic Infections; Pneumonia, Pneumocystis; Tuberculosis; Vidarabine | 1992 |